Back to top

Image: Bigstock

AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Read MoreHide Full Article

For the quarter ended June 2024, AbbVie (ABBV - Free Report) reported revenue of $14.46 billion, up 4.3% over the same period last year. EPS came in at $2.65, compared to $2.91 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $14.05 billion, representing a surprise of +2.96%. The company delivered an EPS surprise of +3.11%, with the consensus EPS estimate being $2.57.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how AbbVie performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Net Revenue- Immunology- Total International: $1.25 billion versus the six-analyst average estimate of $1.24 billion. The reported number represents a year-over-year change of +15.9%.
  • Net Revenue- Immunology- Total US: $5.72 billion versus $5.53 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -0.2% change.
  • Net Revenue- Rinvoq- US: $1.02 billion versus $964.65 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +57.7% change.
  • Net Revenue- Rinvoq- International: $413 million compared to the $385.11 million average estimate based on six analysts. The reported number represents a change of +51.3% year over year.
  • Net Revenue- Eye Care- Total: $533 million compared to the $550.76 million average estimate based on seven analysts. The reported number represents a change of -13.6% year over year.
  • Net Revenue- Aesthetics- Total: $1.39 billion versus $1.47 billion estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +0.4% change.
  • Net Revenue- Neuroscience- Total: $2.16 billion compared to the $2.17 billion average estimate based on seven analysts. The reported number represents a change of +14.7% year over year.
  • Net Revenue- Immunology- Total: $6.97 billion versus the seven-analyst average estimate of $6.77 billion. The reported number represents a year-over-year change of +2.3%.
  • Net Revenue- Qulipta- Total: $150 million compared to the $147.57 million average estimate based on six analysts. The reported number represents a change of +56.3% year over year.
  • Net Revenue- Humira: $2.81 billion versus the six-analyst average estimate of $2.79 billion. The reported number represents a year-over-year change of -29.9%.
  • Net Revenue- Creon: $372 million versus the six-analyst average estimate of $277.41 million. The reported number represents a year-over-year change of +31.9%.
  • Net Revenue- Duodopa: $113 million compared to the $119.30 million average estimate based on six analysts. The reported number represents a change of -3.4% year over year.
View all Key Company Metrics for AbbVie here>>>

Shares of AbbVie have returned +3% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


AbbVie Inc. (ABBV) - free report >>

Published in